Track topics on Twitter Track topics that are important to you
Dr Kirsten Fischer presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the multinational, open-label, phase 3 CLL14 trial. Fixed-duration venetoclax plus obinutuzumab induced deep, high, and long lasting MRD-negativity...NEXT ARTICLE
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...